Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenzumestrocel
- Development stage
- Phase 3
- Lead developer
- Corestemchemon
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Lenzumestrocel is an autologous bone marrow-derived mesenchymal stem cell therapy developed for the treatment of amyotrophic lateral sclerosis (ALS). It is conditionally approved as an orphan drug in South Korea and marketed under the brand name Neuronata-R. The therapy involves extracting bone marrow from the patient, isolating and culturing mesenchymal stem cells (MSCs), and administering them intrathecally. Lenzumestrocel aims to slow ALS progression by targeting neuroinflammation, promoting neuroprotection, preventing motor neuron death, stimulating nerve cell growth, and modulating immune responses through the release of neurotrophic factors and anti-inflammatory molecules. Clinical trials have demonstrated safety and a therapeutic benefit lasting at least six months after administration[3][4][5][7].
- Brand names
- Neuronata-R
- Other names
- Neuronata-R inj.
Beyond the preview
Go deeper on lenzumestrocel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenzumestrocel.